These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37018872)

  • 21. Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.
    Zhou L; Liu R; Huang D; Li H; Ning T; Zhang L; Ge S; Bai M; Wang X; Yang Y; Wang X; Chen X; Gao Z; Luo L; Yang Y; Wu X; Deng T; Ba Y
    EClinicalMedicine; 2021 Nov; 41():101157. PubMed ID: 34765950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial.
    Wang XS; Shi Q; Bhadkamkar NA; Cleeland CS; Garcia-Gonzalez A; Aguilar JR; Heijnen C; Eng C
    J Pain Symptom Manage; 2019 Oct; 58(4):662-671. PubMed ID: 31254639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula: a prospective randomized controlled study.
    Longci P; Chunhui QI; Xubo S; Yixian H; Xinrong Y; Xianjun S
    J Tradit Chin Med; 2023 Oct; 43(6):1234-1242. PubMed ID: 37946486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The associations of oxaliplatin-induced peripheral neuropathy, sociodemographic characteristics, and clinical characteristics with time to fall in older adults with colorectal cancer.
    Hines RB; Schoborg C; Sumner T; Thiesfeldt DL; Zhang S
    Am J Epidemiol; 2024 Sep; 193(9):1271-1280. PubMed ID: 38751324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy.
    Szpejewska JE; Yilmaz M; Falkmer UG; Arendt-Nielsen L; Mørch CD
    Cancer Treat Res Commun; 2022; 31():100543. PubMed ID: 35255440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study.
    Chien A; Yang CC; Chang SC; Jan YM; Yang CH; Hsieh YL
    PM R; 2021 Jan; 13(1):55-65. PubMed ID: 32168417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study.
    Kamei K; Ohnishi T; Nakata K; Danno K; Ohkawa A; Miyake Y; Okazaki S; Fukunaga M; Toyokawa A; Hamada T; Shindoh J; Kanazawa A
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e257-e262. PubMed ID: 32893979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis.
    Kanbayashi Y; Ishikawa T; Kuriu Y; Otsuji E; Takayama K
    PLoS One; 2022; 17(9):e0275481. PubMed ID: 36174022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation.
    Matsumoto Y; Yoshida Y; Kiba S; Yamashiro S; Nogami H; Ohashi N; Kajitani R; Munechika T; Nagano H; Komono A; Aisu N; Yoshimatsu G; Hasegawa S
    Support Care Cancer; 2020 Nov; 28(11):5405-5410. PubMed ID: 32144582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months.
    Zahrieh D; Satele D; Smith EML; Loprinzi CL; Le-Rademacher J
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.
    Aghili M; Darzikolaee NM; Babaei M; Ghalehtaki R; Farhan F; Razavi SZE; Rezaei S; Esmati E; Samiei F; Azadvari M; Farazmand B; Bayani R; Amiri A
    J Gastrointest Cancer; 2023 Jun; 54(2):467-474. PubMed ID: 35426033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.
    Beijers AJM; Bonhof CS; Mols F; Ophorst J; de Vos-Geelen J; Jacobs EMG; van de Poll-Franse LV; Vreugdenhil G
    Ann Oncol; 2020 Jan; 31(1):131-136. PubMed ID: 31912787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    Support Care Cancer; 2023 Oct; 31(12):660. PubMed ID: 37897532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
    Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
    BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
    Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
    Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 40. Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database.
    Mine K; Kawashiri T; Inoue M; Kobayashi D; Mori K; Hiromoto S; Kudamatsu H; Uchida M; Egashira N; Koyanagi S; Ohdo S; Shimazoe T
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.